Global

News Releases

This section features all recent CSL Behring news releases. Click the tabs to select releases in your area of interest. Click Resources to find additional background material on CSL Behring.

All Releases
Corporate
Immunology
Bleeding Disorders
Hereditary Angioedema (HAE)
Pulmonary
Fluid Management
Resources

All Releases

22 March 2017 NEJM Publishes Pivotal Data on Preventing HAE Attacks

The New England Journal of Medicine published data from the COMPACT study which demonstrated the safety and efficacy of CSL830 to prevent HAE attacks.

> Read More
01 March 2017 Largest Ever CIDP Clinical Study Completed

Global biotherapeutics leader CSL Behring announced today that it has completed the largest ever Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) trial, known as PATH (Polyneuropathy And Treatment with Hizentra®).

> Read More
14 February 2017 FDA Accepts CSL Behring’s Biologics License Application Supplement for Using Privigen® to Treat Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), a Rare Neurological Condition

Global biotherapeutics leader CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s clinical efficacy supplement to its Biologics License Application (BLA) for Privigen® [Immune Globulin Intravenous (Human), 10% Liquid], its intravenous immunoglobulin (IVIg).

> Read More
09 January 2017 AFSTYLA®, for Haemophilia A, Receives European Commission Approval

Global biotherapeutics leader CSL Behring announced today that the European Commission has granted marketing authorisation for AFSTYLA® [Recombinant Human Coagulation Factor VIII, Single Chain] for children and adults with haemophilia A.

> Read More
05 January 2017 Momenta and CSL Announce Collaboration and License Agreement to Develop Fc Multimer Programs, Including M230, a Selective Immunomodulator of Fc Receptors

Momenta and CSL have entered into an exclusive research collaboration and worldwide license agreement to develop and commercialize Fc multimer proteins.

> Read More
Page 1 of 7 Next | Last

Share
LinkedIn Twitter Facebook Google+